CSP Study Guide: Multiple Sclerosis (MS)

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/22

flashcard set

Earn XP

Description and Tags

Vocabulary practice flashcards covering Multiple Sclerosis (MS) disease subtypes, disease-modifying therapy (DMT) drug classes, high-yield pharmacology facts, safety monitoring, and relapse management.

23 Terms

1
New cards

Multiple Sclerosis (MS)

chronic, immune-mediated disease of the CNS characterized by inflammation, demyelination, and neuroaxonal injury.

2
New cards

Clinically Isolated Syndrome (CIS)

first neurologic episode suggestive of inflammatory demyelination.

3
New cards

Relapsing-Remitting MS (RRMS)

MS subtype characterized by relapses followed by partial or complete recovery.

4
New cards

Secondary Progressive MS (SPMS)

MS disease course characterized by gradual disability progression following an initial relapsing course; it may be categorized as active or nonactive.

5
New cards

Primary Progressive MS (PPMS)

MS disease subtype defined by disability progression continuous from disease onset.

6
New cards

Disease-Modifying Therapies (DMTs)

Agents that reduce inflammatory disease activity and, depending on the specific therapy and population, slow disability accumulation; they do not cure MS.

7
New cards

Interferon Beta

injectable DMT class associated with flu-like symptoms, depression concerns, and the need for CBC, LFT, and TSH monitoring.

Avonex

Rebif

Betaseron

Extavia

Plegridy

8
New cards

Glatiramer Acetate

A subcutaneous injection DMT associated with injection-site reactions and transient post-injection reactions.

Copaxone

Glatopa

9
New cards

Fumarates

An oral DMT class associated with flushing, GI effects, lymphopenia, and PML risk.

Tecfidera

Vumerity

Bafiertam

10
New cards

S1P Receptor Modulators

An oral DMT class associated with bradycardia, macular edema, infection risk, and rebound disease activity after discontinuation.

Gilenya

Mayzent

Zeposia

Ponvory

11
New cards

Anti-CD20 Monoclonal Antibodies

A DMT class that causes B-cell depletion and requires HBV screening, infection monitoring, and quantitative immunoglobulin monitoring.

Ocrevus

Kesimpta

Briumvi

12
New cards

ocrelizumab

Ocrevus

IV anti-CD20 monoclonal antibody administered every 6 months after initial split dosing; it is FDA-approved for relapsing forms of MS and primary progressive MS (PPMS).

13
New cards

ofatumumab

Kesimpta

at-home subcutaneous self-injection anti-CD20 therapy given as loading doses at weeks 0, 1, and 2, followed by monthly maintenance starting at week 4.

14
New cards

natalizumab

Tysabri

anti-α4 integrin monoclonal antibody given IV every 4 weeks that blocks leukocyte migration into the CNS; associated with progressive multifocal leukoencephalopathy (PML) and managed via TOUCH REMS.

15
New cards

siponimod

Mayzent

oral, once-daily S1P modulator used particularly in active SPMS that requires CYP2C9 genotyping prior to initiation (CYP2C9 3/3 genotype is contraindicated).

16
New cards

fingolimod

Gilenya

oral, once-daily S1P modulator requiring first-dose cardiac observation due to bradycardia and AV block risks; also associated with macular edema, infections, and severe rebound MS activity upon stopping.

17
New cards

teriflunomide

Aubagio

oral, once-daily pyrimidine synthesis inhibitor associated with hepatotoxicity and embryo-fetal toxicity, possessing a long elimination period that can be cleared via an accelerated elimination procedure.

18
New cards

Accelerated Elimination Procedure

A washout regimen using cholestyramine or activated charcoal to rapidly eliminate Aubagio (teriflunomide) from the body.

19
New cards

cladribine


Mavenclad

oral purine antimetabolite administered in short courses over two years (not continuously); requires lymphocyte monitoring and carries warnings for malignancy and embryo-fetal toxicity.

20
New cards

lemtuzumab

Lemtrada

anti-CD52 monoclonal antibody associated with autoimmune disorders (including autoimmune thyroid disease and ITP), infusion reactions, and prolonged monitoring.

21
New cards

Progressive Multifocal Leukoencephalopathy (PML)

A serious viral brain infection associated with natalizumab and fumarates; risk increases with anti-JCV antibody positivity, longer treatment duration, and prior immunosuppression.

22
New cards

Acute MS Relapse Management

Short-term treatment using high-dose corticosteroids (typically IV methylprednisolone or an equivalent high-dose oral regimen), or plasma exchange for severe steroid-refractory attacks, to accelerate clinical recovery.

23
New cards

Pseudo-relapse

A temporary worsening of preexisting neurologic symptoms triggered by infection, fever, or overheating, occurring without new inflammatory demyelinating disease activity.